Wuhan YZY Biopharma Co., Ltd.

2496 · HKEX

Public Market Listing

2496HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Wuhan YZY Biopharma Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
EpCAM x CD3Multispecific antibody
Non-Small Cell Lung Cancer
Phase 1
CD38 (tumor cells) x CD3 (T cells)Multispecific antibody
Multiple Myeloma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$5.1M——$4.1Mreport ↗

Wuhan YZY Biopharma Co., Ltd. reported revenue of $5.13M and a net loss of $8.12M for H1 2025.

Figures only: this period's report disclosed no narrative text

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$9.3M—$14M$3.0Mreport ↗